Articles

Tackling resistance to anti-EGFR therapies, from challenges to re-challenge

Since their first approval and use, more than 15 years ago, inhibitors of the Epidermal Growth Factor Receptor (EGFRi) have revolutionized the clinical practice and the prognosis for cancer patients, especially those diagnosed with colorectal (CRC) and lung cancer. These drugs rapidly shifted the treatment paradigm of the two malignancies from traditional chemotherapy to targeted […]